ea0086p168 | Adrenal and Cardiovascular | SFEBES2022
, Sabbour Hani
, Ashraf Tanveer
, Buckley Adam
Background: Inclisiran is the first clinically available small interfering RNA (siRNA)-based treatment, has been shown to reduce pro-atherogenic lipoproteins in patients with or without familial hypercholesterolemia (FH), diabetes mellitus (DM), or atherosclerotic cardiovascular disease (ASCVD), but has not been evaluated in Middle Eastern populations.Methods: Retrospective review of patients initiating inclisiran treatment for any indication at our cent...